STAT6 inhibitor
Immunology/Inflammatory diseases
PreclinicalActive
Key Facts
About QuantX Biosciences
QuantX Biosciences is an emerging biotech leveraging advanced computational modeling and high-performance computing to accelerate the discovery of oral small molecule drugs. Founded in 2022 by veteran drug hunters and incubated by OrbiMed and Creacion Ventures, the company has rapidly built a pipeline targeting immunology and inflammation, with its lead programs advancing toward IND-enabling studies. The company recently secured an oversubscribed $85M Series B financing co-led by Sanofi Ventures and LAV, bringing its total funding to $130M, which will support clinical development of its STAT6 and IL-17 inhibitors.
View full company profileTherapeutic Areas
Other Immunology/Inflammatory diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| IL-17 inhibitor | QuantX Biosciences | Preclinical |